3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
5
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Conditions
Carcinoma, Non-Small-Cell Lung
31
Lung Neoplasms
9
Small Cell Lung Carcinoma
7
Biliary Tract Neoplasms
7
Carcinoma, Hepatocellular
6
Urinary Bladder Neoplasms
4
Liver Neoplasms
4
Carcinoma
4
Neoplasm Metastasis
3
Breast Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
2
Small Cell Lung Carcinoma Extensive Disease
2
Recurrence
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Non-Muscle Invasive Bladder Neoplasms
2
Gallbladder Neoplasms
2
Endometrial Neoplasms
2
Carcinoma, Renal Cell
2
Urothelial Cancer
1
Sarcoma
1
Radiation Pneumonitis
1
Pancoast Syndrome
1
Ovarian Neoplasms
1
Oropharyngeal Neoplasms
1
Non Small Cell Lung Carcinoma NSCLC
1
Non Small Cell Lung Cancer NSCLC
1
Non - Small Cell Lung Cancer NSCLC
1
Neoplasms
1
Mesothelioma, Malignant
1
Mesothelioma
1
Interventions
Cisplatin
6
Pemetrexed
4
Carboplatin
3
Nivolumab
2
Ipilimumab
2
tumor necrosis factor-alpha, CNGRC fusion protein, human
1
ranpirnase
1
raltitrexed
1
durvalumab
1
atezolizumab
1
Vinorelbine
1
Vincristine
1
Talc
1
Radiotherapy, Intensity-Modulated
1
Radiotherapy
1
Psychiatric Rehabilitation
1
Platinum
1
Mitomycin
1
Injections
1
Gemcitabine
1
Fentanyl
1
Drug Therapy
1
Doxorubicin
1
Cerebral Decortication
1
Analgesia
1
1,2-diaminocyclohexaneplatinum II citrate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Mesothelioma, Malignant
×
durvalumab
×
Clear all
NCT04334759
2026-01-22
DREAM3R
PrECOG, LLC.
Phase 3
Completed
214 enrolled